reason report
bottom line yesterday triniti trial result
decis seek acceler approv rova-t small cell
lung cancer sclc see note question
product platform disclosur
decid remov rova-t model altogeth reduc
revenu forecast beyond ep estim
leav long-term revenu earn forecast
respect current consensu
compani base chang chang peer compani
multipl lower price target
reiter market perform rate stock close
market cap day yesterday frankli
seem excess view given rova-t contribut
consensu buy side expect howev note
yesterday investor disappoint reflect unravel
compani overal solid tumor oncolog strategi well
question busi develop disciplin judgement
qualiti reliabl manag long-term revenu
forecast said month ago good come long-
term forecast environ uncertainti abbvi
forecast come adrift even quicker
first major test manag non-humira guidanc
investor like re-examin reliabl
compani view develop candid includ
forecast disappoint correct abbvi
stock yesterday seem excess view would
expect recoveri come day stock continu
weaken valu territori may offer opportun
patient investor valu orient
base margin benefit substanti risk remov
rova-t model compani disclos result
rova-t peculiar fashion prompt result prompt
regulatori decis top-lin data press releas indic
rova-t best similar surviv benefit histor outcom
chemotherapi sclc includ signific toler
concern high rate pulmonari hematolog toxic
report trial rais concern mind whether rova-t
ever approv least absenc clariti
time on-going phase trial hard us forecast
approv might occur profil drug would
set next data disclosur trial like come
american societi clinic oncolog meet june
see granular detail safeti efficaci
compani inform leerink partner llc research
revenu mm dilut ep includ option expens present
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
pleas refer page import disclosur price chart analyst certif
includ data entir subject studi popul
sclc trial still recruit patient unlik
report data question whether drug profil
disclos triniti pose challeng enrol trial
sharp drop stock valu occur could typic
lead re-evalu rate see meaning catalyst
remaind year oper result
major catalyst includ regulatori approv
submiss asset alreadi reflect consensu
elagolix upadacitinib risankizumab major clinic catalyst
watch two remain upadacitinib rheumatoid
arthriti trial believ outcom event still
downsid bia manag guidanc upadacitinib
across multipl indic safeti profil alreadi
blemish multipl report venou thromboembol event vte
believ report vte two trial would heighten
concern approv critic asset clean success
unlik increas consensu estim materi
rova-t consensu forecast manag long-term
reliabl question previous includ modest revenu
contribut rova-t model prior forecast includ sale
grew recent consensu
estim like reduc substanti complet
forecast peak sale
expect consensu revenu ep estim reduc
slightli longer term recal
provid long-term sale guidanc asset
earn call consist nomin
non-humira sale guidanc figur unlik revis
manag similarli unlik endors investor
leerink model updat remov rova-t pt
remov rova-t model revenu attribut
pipelin product decreas
total revenu also decreas
near-term revenu estim
consensu longer term reduc
oper expens result ep
decreas ep estim
line consensu
base revis model
recent narrow peer compani multipl lower price
target maintain market perform rate
stock
price target per share stock rate market perform
transit corpor ownership success independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil growth rate matur biotechnolog compani remain
highli depend singl franchis humira sale total sale
suggest us valuat still discount compar diversifi
peer us biosimilar settlement competitor mp appear reassur
investor fear biosimilar entri exagger invalid expect oncolog
product imbruvica venclexta becom signific product gener
revenu compani next-gener hcv regimen
boost market share consider declin market look compani
array promis late-stag clinic medicin inflamm metabol diseas
struggl expand oncolog franchis beyond imbruvica venclexta current pipelin
product contribut revenu growth unlik materi dilut
massiv headwind face biosimilar enter market compet humira
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk rhhbi sni nv celg
averag consensu ep multipl appli current ep estim
give valu use revenu multipl similar
compani consensu sale appli revenu estim
give valu lastli dcf valuat given wacc
termin cash flow growth rate begin humira biosimilar entri give
present valu averag three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi assum oper margin increas current level
toward fail reach sustain level would advers affect
forecast valuat also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep rhhbi sni celg
leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
mid-term growth tail risk nv azn celg
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current leerink dcf marketed/l stage program
sourc leerink partner estim compani file factset
